Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
443 Pembrolizumab for BCG refractory non-muscle invasive bladder cancer yields poor recurrence-free survival and high toxicity in patients
Compose a Response to This Article
Other responses
No responses have been published for this article.
